WO2012115772A3 - Therapy for kidney disease and/or heart failure - Google Patents

Therapy for kidney disease and/or heart failure Download PDF

Info

Publication number
WO2012115772A3
WO2012115772A3 PCT/US2012/024207 US2012024207W WO2012115772A3 WO 2012115772 A3 WO2012115772 A3 WO 2012115772A3 US 2012024207 W US2012024207 W US 2012024207W WO 2012115772 A3 WO2012115772 A3 WO 2012115772A3
Authority
WO
WIPO (PCT)
Prior art keywords
heart failure
kidney disease
methods
therapy
alone
Prior art date
Application number
PCT/US2012/024207
Other languages
French (fr)
Other versions
WO2012115772A2 (en
Inventor
William Van Antwerp
Andrew J. L. WALSH
Venkatesh R. MANDA
John Burnes
Original Assignee
Medtronic, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic, Inc. filed Critical Medtronic, Inc.
Priority to EP12704214.1A priority Critical patent/EP2678002A2/en
Publication of WO2012115772A2 publication Critical patent/WO2012115772A2/en
Publication of WO2012115772A3 publication Critical patent/WO2012115772A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14212—Pumping with an aspiration and an expulsion action
    • A61M5/14228—Pumping with an aspiration and an expulsion action with linear peristaltic action, i.e. comprising at least three pressurising members or a helical member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

Medical systems and methods for treating kidney disease alone, heart failure alone, chronic kidney disease with concomitant heart failure, or cardiorenal syndrome are described. The systems and methods are based on delivery of a natriuretic peptide such as Vessel Dilator to a subject. Methods for increasing and maintaining peptide levels at a certain concentration include direct peptide delivery via either an external or implantable programmable pump.
PCT/US2012/024207 2011-02-25 2012-02-07 Therapy for kidney disease and/or heart failure WO2012115772A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP12704214.1A EP2678002A2 (en) 2011-02-25 2012-02-07 Therapy for kidney disease and/or heart failure

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201161446995P 2011-02-25 2011-02-25
US61/446,995 2011-02-25
US201161511509P 2011-07-25 2011-07-25
US61/511,509 2011-07-25
US201161550896P 2011-10-24 2011-10-24
US61/550,896 2011-10-24
US201161565911P 2011-12-01 2011-12-01
US61/565,911 2011-12-01

Publications (2)

Publication Number Publication Date
WO2012115772A2 WO2012115772A2 (en) 2012-08-30
WO2012115772A3 true WO2012115772A3 (en) 2013-01-10

Family

ID=45607416

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/024207 WO2012115772A2 (en) 2011-02-25 2012-02-07 Therapy for kidney disease and/or heart failure

Country Status (3)

Country Link
US (2) US20120277155A1 (en)
EP (1) EP2678002A2 (en)
WO (1) WO2012115772A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011005939A2 (en) 2009-07-09 2011-01-13 Mayo Foundation For Medical Education And Research Long acting atrial natriuretic peptide (la-anp) and methods for use thereof
WO2012019237A1 (en) 2010-08-12 2012-02-16 Madeleine Pharmaceuticals Pty Ltd Therapeutic method for treating congestive heart failure
US20120277155A1 (en) 2011-02-25 2012-11-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
EP2741762A4 (en) * 2011-07-27 2015-04-15 Natriuretic peptide compositions and methods of preparation
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
EP2751136B1 (en) 2011-08-30 2017-10-18 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
WO2013033675A1 (en) 2011-09-02 2013-03-07 Medtronic, Inc. Chimeric natriuretic peptide compositions and methods of preparation
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
CN104364378A (en) * 2012-03-19 2015-02-18 麦德林制药私人有限公司 Method of producing a recombinant peptide
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
US20140274901A1 (en) * 2013-03-12 2014-09-18 Mayo Foundation For Medical Education And Research Proanp compositions and methods for treating acute heart failure
WO2014138796A1 (en) 2013-03-15 2014-09-18 Madeleine Pharmaceuticals Pty Ltd Dosage regimen for therapeutic method
AU2015230778B2 (en) * 2013-03-15 2017-06-29 Madeleine Pharmaceuticals Pty Ltd Dosage regimen for therapeutic method
WO2015070161A1 (en) 2013-11-11 2015-05-14 Medtronic, Inc. Drug delivery programming techniques
US9314572B2 (en) 2013-11-11 2016-04-19 Medtronic, Inc. Controlling drug delivery transitions
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
US10004754B2 (en) 2014-03-14 2018-06-26 Madeleine Pharmaceuticals Pty Ltd. ANP fragment adjuvant therapy to standard of care (SOC) diuretic treatment
US20160085415A1 (en) * 2014-09-23 2016-03-24 Koninklijke Philips N.V. Multi-parameter, risk-based early warning and alarm decision support with progressive risk pie visualizer
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
WO2016131943A1 (en) * 2015-02-20 2016-08-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of obesity and complications arising therefrom including type 2 diabetes
US10493232B2 (en) 2015-07-20 2019-12-03 Strataca Systems Limited Ureteral catheters, bladder catheters, systems, kits and methods for inducing negative pressure to increase renal function
US10926062B2 (en) 2015-07-20 2021-02-23 Strataca Systems Limited Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
US11541205B2 (en) 2015-07-20 2023-01-03 Roivios Limited Coated urinary catheter or ureteral stent and method
US11040180B2 (en) 2015-07-20 2021-06-22 Strataca Systems Limited Systems, kits and methods for inducing negative pressure to increase renal function
US9744331B2 (en) 2015-07-20 2017-08-29 Strataca Systems, LLC Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
US10765834B2 (en) 2015-07-20 2020-09-08 Strataca Systems Limited Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
US11229771B2 (en) 2015-07-20 2022-01-25 Roivios Limited Percutaneous ureteral catheter
US10512713B2 (en) 2015-07-20 2019-12-24 Strataca Systems Limited Method of removing excess fluid from a patient with hemodilution
US11040172B2 (en) 2015-07-20 2021-06-22 Strataca Systems Limited Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
US10918827B2 (en) 2015-07-20 2021-02-16 Strataca Systems Limited Catheter device and method for inducing negative pressure in a patient's bladder
WO2017210377A1 (en) * 2016-06-02 2017-12-07 Cardiac Pacemakers, Inc. Acute kidney injury detection system and methods
US10918778B2 (en) * 2017-05-24 2021-02-16 Sequana Medical Nv Direct sodium removal method, solution and apparatus to reduce fluid overload in heart failure patients
DE102018201030A1 (en) 2018-01-24 2019-07-25 Kardion Gmbh Magnetic coupling element with magnetic bearing function
DE102018206754A1 (en) 2018-05-02 2019-11-07 Kardion Gmbh Method and device for determining the temperature at a surface and use of the method
DE102018206724A1 (en) 2018-05-02 2019-11-07 Kardion Gmbh Energy transmission system and method for wireless energy transmission
US11419917B2 (en) 2020-04-07 2022-08-23 Drora Shevy Treatment for SARS-CoV-2 and other coronaviruses
WO2022029497A1 (en) * 2020-08-06 2022-02-10 Ads Aiphia Development Services Ag Ularitide for use in methods of treating refractory ascites
US11699551B2 (en) 2020-11-05 2023-07-11 Kardion Gmbh Device for inductive energy transmission in a human body and use of the device

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135912A (en) * 1988-05-27 1992-08-04 Tosoh Corporation Natriuretic peptides from the pituitary prohormone proopiomelanocortin
US20040077537A1 (en) * 2002-03-18 2004-04-22 Schreiner George F. Method for treating congestive heart failure
US20070042957A1 (en) * 2005-08-19 2007-02-22 Mayo Foundation For Medical Education And Research Type v phosphodiesterase inhibitors and natriuretic polypeptides
WO2009149161A2 (en) * 2008-06-06 2009-12-10 Mayo Foundation For Medical Education And Research Chimeric natriuretic polypeptides and methods for inhibiting cardiac remodeling
WO2012019237A1 (en) * 2010-08-12 2012-02-16 Madeleine Pharmaceuticals Pty Ltd Therapeutic method for treating congestive heart failure
WO2012058585A2 (en) * 2010-10-29 2012-05-03 Nile Therapeutics, Inc. Methods of treatment with natriuretic peptides

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761469A (en) 1982-02-22 1988-08-02 Queen's University At Kingston Isolation, purification and sequence determination of cardionatrins
US4569641A (en) 1982-09-07 1986-02-11 Greatbatch Enterprises, Inc. Low power electromagnetic pump
DE3346953A1 (en) 1983-12-24 1985-08-14 Organogen Medizinisch-Molekularbiologische Forschungsgesellschaft mbH, 6900 Heidelberg CARDIODILATIN, A NEW PEPTIDE HORMONE AND METHOD FOR THE PRODUCTION THEREOF
US4562751A (en) 1984-01-06 1986-01-07 Nason Clyde K Solenoid drive apparatus for an external infusion pump
US4685903A (en) 1984-01-06 1987-08-11 Pacesetter Infusion, Ltd. External infusion pump apparatus
US4508712A (en) 1984-01-10 1985-04-02 Washington University Atrial peptide
US4851349A (en) 1984-04-12 1989-07-25 Mitsubishi Chemical Industries Limited Expression vectors encoding cardionatrin and cardiodilatin
US4618600A (en) 1984-04-19 1986-10-21 Biotechnology Research Associates, J.V. Novel polypeptide diuretic/vasodilators
US5212286A (en) 1984-04-19 1993-05-18 Scios Nova Inc. Atrial natriuretic/vasodilator peptide compounds
JPH0780907B2 (en) 1984-04-19 1995-08-30 シオス・ノバ・インク A novel atrial natriuretic and vasodilatory polypeptide
EP0287920B1 (en) 1987-04-22 1991-05-15 Siemens Aktiengesellschaft Piston pump for a device for dosing medicaments
US5691310A (en) 1987-09-29 1997-11-25 Vesely; David L. Methods of treatment using proANF peptides
CA1339210C (en) 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5097122A (en) 1990-04-16 1992-03-17 Pacesetter Infusion, Ltd. Medication infusion system having optical motion sensor to detect drive mechanism malfunction
US5080653A (en) 1990-04-16 1992-01-14 Pacesetter Infusion, Ltd. Infusion pump with dual position syringe locator
EP0465097A3 (en) 1990-06-26 1993-03-24 Merck & Co. Inc. Peptides having atrial natriuretic factor activity
US5202239A (en) 1990-08-07 1993-04-13 Scios Nova Inc. Expression of recombinant polypeptides with improved purification
US5395340A (en) 1993-03-15 1995-03-07 Lee; Tzium-Shou Infusion pump and a method for infusing patients using same
US5665704A (en) 1993-11-12 1997-09-09 Genentech, Inc. Receptor specific atrial natriuretic peptides
US6525022B1 (en) 1993-11-12 2003-02-25 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5846932A (en) 1993-11-12 1998-12-08 Genentech, Inc. Receptor specific atrial natriuretic peptides
US6150402A (en) 1994-08-15 2000-11-21 Loma Linda University Medical Center Natriuretic compounds
US5505709A (en) 1994-09-15 1996-04-09 Minimed, Inc., A Delaware Corporation Mated infusion pump and syringe
US6136564A (en) 1995-11-16 2000-10-24 Roche Diagnostics Gmbh Process for the production of peptides by way of streptavidin fusion proteins
FR2755976B1 (en) 1996-11-15 1999-01-15 Idm Immuno Designed Molecules NOVEL COMPLEXES OF NUCLEIC ACIDS AND POLYMER SUBSTITUTED BY RESIDUES CAUSING THE DESTABILIZATION OF CELL MEMBRANES
US6558351B1 (en) 1999-06-03 2003-05-06 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
IL138214A0 (en) 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6554798B1 (en) 1998-08-18 2003-04-29 Medtronic Minimed, Inc. External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities
US6558320B1 (en) 2000-01-20 2003-05-06 Medtronic Minimed, Inc. Handheld personal data assistant (PDA) with a medical device and method of using the same
EP1118329A4 (en) 1998-09-28 2004-12-15 Santen Pharmaceutical Co Ltd Lacrimal secretion promoters or eye drops for treating keratoconjunctival failure containing as the active ingredient natriuretic peptides
US6800071B1 (en) 1998-10-29 2004-10-05 Medtronic Minimed, Inc. Fluid reservoir piston
US6817990B2 (en) 1998-10-29 2004-11-16 Medtronic Minimed, Inc. Fluid reservoir piston
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20090175821A1 (en) 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
AU5043900A (en) 1999-05-24 2000-12-12 Mayo Foundation For Medical Education And Research Adenovirus vectors encoding brain natriuretic peptide
US6752787B1 (en) 1999-06-08 2004-06-22 Medtronic Minimed, Inc., Cost-sensitive application infusion device
US6423035B1 (en) 1999-06-18 2002-07-23 Animas Corporation Infusion pump with a sealed drive mechanism and improved method of occlusion detection
DE19942230C2 (en) 1999-09-03 2003-09-25 Wolf-Georg Forssmann Use of natriuretic peptides as antibiotic substances for the treatment of bacterial infections
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
US6629954B1 (en) 2000-01-31 2003-10-07 Medtronic, Inc. Drug delivery pump with isolated hydraulic metering
JP4483009B2 (en) 2000-03-21 2010-06-16 パナソニック株式会社 Motor control device
US20010041869A1 (en) 2000-03-23 2001-11-15 Causey James D. Control tabs for infusion devices and methods of using the same
US6485465B2 (en) 2000-03-29 2002-11-26 Medtronic Minimed, Inc. Methods, apparatuses, and uses for infusion pump fluid pressure and force detection
JP4237375B2 (en) 2000-03-31 2009-03-11 アスビオファーマ株式会社 Pharmaceutical composition used for treatment or prevention of ischemic disease
US6652493B1 (en) 2000-07-05 2003-11-25 Animas Corporation Infusion pump syringe
US6589229B1 (en) 2000-07-31 2003-07-08 Becton, Dickinson And Company Wearable, self-contained drug infusion device
US20040053245A1 (en) 2001-02-05 2004-03-18 Tang Y. Tom Novel nucleic acids and polypeptides
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
US7288085B2 (en) 2001-04-10 2007-10-30 Medtronic, Inc. Permanent magnet solenoid pump for an implantable therapeutic substance delivery device
US20040176914A1 (en) 2001-04-13 2004-09-09 Biosite Incorporated Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
KR101271635B1 (en) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 Albumin fusion proteins
US20050106592A1 (en) 2002-02-20 2005-05-19 Paion Gmbh Method for identifying a pharmacologically active substance
US20050113286A1 (en) 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
IL149562A0 (en) 2002-05-09 2002-11-10 Prochon Ltd Fgf variants and methods for use thereof
US20060110359A1 (en) 2002-09-06 2006-05-25 Juan Sanchez-Ramos Cellular delivery of natriuretic peptides
US20080214437A1 (en) 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
US7655772B2 (en) 2002-09-06 2010-02-02 University Of South Florida Materials and methods for treatment of allergic diseases
US7128727B2 (en) 2002-09-30 2006-10-31 Flaherty J Christopher Components and methods for patient infusion device
US7144384B2 (en) 2002-09-30 2006-12-05 Insulet Corporation Dispenser components and methods for patient infusion device
WO2004033036A2 (en) * 2002-10-04 2004-04-22 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
CA2504287A1 (en) 2002-11-26 2004-06-10 Nobex Corporation Natriuretic compounds, conjugates, and uses thereof
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US6932584B2 (en) 2002-12-26 2005-08-23 Medtronic Minimed, Inc. Infusion device and driving mechanism and process for same with actuator for multiple infusion uses
US7488713B2 (en) 2004-03-18 2009-02-10 University Of South Florida Cancer treatment using C-type natriuretic peptides
WO2004089280A2 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
CA2522709A1 (en) 2003-04-17 2004-11-04 Ciphergen Biosystems, Inc. Polypeptides related to natriuretic peptides and methods of their identification and use
WO2005019819A1 (en) 2003-08-20 2005-03-03 Biosite, Inc. Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential
US20050065760A1 (en) 2003-09-23 2005-03-24 Robert Murtfeldt Method for advising patients concerning doses of insulin
WO2005052593A1 (en) 2003-10-29 2005-06-09 The University Of Leicester Detection
US7714100B2 (en) 2004-01-27 2010-05-11 Compugen Ltd Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of cardiac disease
PL1729795T3 (en) 2004-02-09 2016-08-31 Human Genome Sciences Inc Albumin fusion proteins
CA2559853A1 (en) 2004-02-17 2005-10-13 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
US7642243B2 (en) 2004-03-31 2010-01-05 Kazuwa Nakao Method of treating arthritis and promoting growth of articular chondrocytes
JP4972403B2 (en) 2004-03-31 2012-07-11 一和 中尾 Height-enhancing composition
AU2005329255B2 (en) 2004-04-15 2010-09-30 Chiasma, Inc. Compositions capable of facilitating penetration across a biological barrier
EP1773867B1 (en) 2004-07-15 2011-01-19 The University Of Queensland Proteinaceous compounds and uses therefor
US7938817B2 (en) 2004-09-09 2011-05-10 Plc Medical Systems, Inc. Patient hydration system and method
WO2006076471A2 (en) 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
EA011653B1 (en) 2005-02-11 2009-04-28 Амилин Фармасьютикалз, Инк. Gip analog and hybrid polypeptides with selectable properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
US20060205642A1 (en) 2005-03-08 2006-09-14 Vesely David L Oral methods of treatment using proANF peptides
PL1865976T3 (en) * 2005-04-07 2012-11-30 Cardiorentis Ag Use of natriuretic peptide for treating heart failure
US20080097291A1 (en) 2006-08-23 2008-04-24 Hanson Ian B Infusion pumps and methods and delivery devices and methods with same
EP1922336B1 (en) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
WO2007035600A2 (en) 2005-09-16 2007-03-29 Mayo Foundation For Education And Research Natriuretic activities
US20090035287A1 (en) 2005-09-26 2009-02-05 Zurit Levine Atrial natriuretic peptide (anp) splice variants and methods of using same
JP2009511060A (en) 2005-10-14 2009-03-19 バイオレクシス ファーマシューティカル コーポレーション Natriuretic peptide modified transferrin fusion protein
WO2007130672A2 (en) 2006-05-05 2007-11-15 University Of South Florida Urodilatin cancer treatment
WO2008019147A2 (en) 2006-08-04 2008-02-14 Amylin Pharmaceuticals, Inc. Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
US8324162B2 (en) 2006-08-08 2012-12-04 Mayo Foundation For Medical Education And Research Diuretic and natriuretic polypeptides lacking the blood pressure lowering property
US7825092B2 (en) 2006-08-08 2010-11-02 University Of South Florida Dendroaspis natriuretic peptide for treatment of cancer
US8283318B2 (en) 2006-09-08 2012-10-09 Mayo Foundation For Medical Education And Research Aquaretic and natriuretic polypeptides lacking vasodilatory activity
US20080181903A1 (en) 2006-12-21 2008-07-31 Pdl Biopharma, Inc. Conjugate of natriuretic peptide and antibody constant region
JP4940956B2 (en) 2007-01-10 2012-05-30 ヤマハ株式会社 Audio transmission system
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
US8504152B2 (en) 2007-04-04 2013-08-06 Pacesetter, Inc. System and method for estimating cardiac pressure based on cardiac electrical conduction delays using an implantable medical device
US20080300572A1 (en) 2007-06-01 2008-12-04 Medtronic Minimed, Inc. Wireless monitor for a personal medical device system
MX2009013372A (en) 2007-07-06 2010-02-22 Theratechnologies Inc Bifunctional fusion proteins of the alpha-melanocyte stimulating hormone (alpha-msh) and atrial natriuretic protein (anp) and uses in hypertension and acute kidney injury.
WO2009015011A1 (en) 2007-07-20 2009-01-29 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
US20090062728A1 (en) 2007-09-01 2009-03-05 Sang Hoon Woo Control of Body Fluid Condition Using Diuretics, Based on Weight Measurement
KR20100056517A (en) 2007-09-11 2010-05-27 몬도바이오테크 래보래토리즈 아게 Use of a peptide as a therapeutic agent
WO2009040083A2 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
AU2008303909A1 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of Tyr-w-Mif-1 and urocortin 2 as therapeutic agents
CA2698971A1 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of urodilatin as a therapeutic agent
US20090281528A1 (en) 2008-05-12 2009-11-12 Medtronic, Inc. Osmotic pump apparatus and associated methods
WO2010033216A1 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of nesiritide peptides
US8642550B2 (en) 2008-10-24 2014-02-04 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides without hypotensive inducing capability
RU2011125366A (en) 2008-12-05 2013-01-10 Ангиочем Инк. CONJUGATES OF THERAPEUTIC PEPTIDES AND THEIR APPLICATION
WO2010078325A2 (en) 2008-12-29 2010-07-08 Mayo Foundation For Medical Education And Research Natriuretic polypeptides for reducing or preventing restenosis
US20100298901A1 (en) 2009-05-19 2010-11-25 Medtronic, Inc. Implantable medical device for cardiac electrical stimulation
AR078044A1 (en) 2009-05-20 2011-10-12 Biomarin Pharm Inc VARIANTS OF NATURAL PEPTIDES OF TYPE C
US20120220528A1 (en) 2011-02-25 2012-08-30 Medtronic, Inc. Systems and methods for therapy of kidney disease and/or heart failure using chimeric natriuretic peptides
US20120277155A1 (en) 2011-02-25 2012-11-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
EP2741762A4 (en) 2011-07-27 2015-04-15 Natriuretic peptide compositions and methods of preparation
WO2013019237A1 (en) 2011-08-03 2013-02-07 Celanese International Corporation Reducing acetals and/or esters during ethanol separation process
WO2013033675A1 (en) 2011-09-02 2013-03-07 Medtronic, Inc. Chimeric natriuretic peptide compositions and methods of preparation
WO2013154783A1 (en) 2012-04-13 2013-10-17 Medtronic, Inc. Feedback-based diuretic or natriuretic molecule administration
US20130274705A1 (en) 2012-04-13 2013-10-17 Medtronic, Inc. Feedback-based diuretic or natriuretic molecule administration

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135912A (en) * 1988-05-27 1992-08-04 Tosoh Corporation Natriuretic peptides from the pituitary prohormone proopiomelanocortin
US20040077537A1 (en) * 2002-03-18 2004-04-22 Schreiner George F. Method for treating congestive heart failure
US20070042957A1 (en) * 2005-08-19 2007-02-22 Mayo Foundation For Medical Education And Research Type v phosphodiesterase inhibitors and natriuretic polypeptides
WO2009149161A2 (en) * 2008-06-06 2009-12-10 Mayo Foundation For Medical Education And Research Chimeric natriuretic polypeptides and methods for inhibiting cardiac remodeling
WO2012019237A1 (en) * 2010-08-12 2012-02-16 Madeleine Pharmaceuticals Pty Ltd Therapeutic method for treating congestive heart failure
WO2012058585A2 (en) * 2010-10-29 2012-05-03 Nile Therapeutics, Inc. Methods of treatment with natriuretic peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HORNG H. CHEN, J. AARON GRANTHAM, JOHN A. SCHIRGER: "Subcutaneous administration of brain natriuretic peptide in experimental heart failure", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 36, no. 5, 19 June 2000 (2000-06-19), pages 1706 - 1712, XP002686550, ISSN: 0735-1097 *

Also Published As

Publication number Publication date
US20150190473A1 (en) 2015-07-09
WO2012115772A2 (en) 2012-08-30
US20120277155A1 (en) 2012-11-01
EP2678002A2 (en) 2014-01-01
US9616107B2 (en) 2017-04-11

Similar Documents

Publication Publication Date Title
WO2012115772A3 (en) Therapy for kidney disease and/or heart failure
WO2012115771A3 (en) Systems and methods for therapy of kidney disease and/or heart failure using chimeric natriuretic peptides
WO2013151767A8 (en) Therapy for kidney disease and/or heart failure by intradermal infusion
PH12018501969A1 (en) Pharmaceutical composition comprising empagliflozin and uses thereof
BR112013032265A2 (en) continuous subcutaneous insulin infusion methods with a hyaluronan degradation enzyme
WO2012058585A3 (en) Treatment of heart failure with natriuretic peptides
WO2014197632A3 (en) Methods, systems and devices for reducing the luminal surface area of the gastrointestinal tract
PH12015502275B1 (en) Therapuetic uses of empagliflozin
WO2013186240A3 (en) Exendin-4 peptide analogues
WO2013092703A3 (en) Glucagon analogues
MX2020010004A (en) Therapeutic uses of empagliflozin.
WO2009140657A3 (en) Method of treating chronic heart failure
WO2011103477A3 (en) Vascular patency management using electric fields
MX2023000796A (en) Pharmaceutical composition, methods for treating and uses thereof.
WO2014058905A3 (en) Potassium-binding agents for treating hypertension and hyperkalemia
EP3277338A4 (en) Cannula system with sterile connector, blood pump, and patient harness
MX357071B (en) Method of treating diabetes using non-glycosylated apolipoprotein a-iv.
WO2015106296A8 (en) Enolase 1 (eno1) compositions and uses thereof
WO2014152754A3 (en) Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
EP4010062A4 (en) Catheter blood pump delivery, guiding systems and methods of use
MX2020003243A (en) Methods of treating heart failure with preserved ejection fraction.
De Vecchis et al. Efficacy and safety assessment of isolated ultrafiltration compared to intravenous diuretics for acutely decompensated heart failure: a systematic review with meta-analysis
WO2011056850A3 (en) Linaclotide for the treatment of chronic constipation
WO2015017218A3 (en) Titration for medical infusion devices and systems
EP4084764A4 (en) Venous blood flow stimulator for extracorporeal therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12704214

Country of ref document: EP

Kind code of ref document: A2

REEP Request for entry into the european phase

Ref document number: 2012704214

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012704214

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE